DTaP-IPV-HepB-Hib Vaccine (Hexyon®): An Updated Review of its Use in Primary and Booster Vaccination
Hexyon® is a fully-liquid, ready-to-use, hexavalent vaccine approved in the EU since 2013 for primary and booster vaccination in infants and toddlers from age 6 weeks against diphtheria, tetanus, pertussis, hepatitis B (HB), poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b (Hib). While the source of HB antigen in Hexyon® is different from other vaccines, the rest of its valences have been extensively used in other approved vaccines. Hexyon® is highly immunogenic for all its component toxoids/antigens when used as primary and booster vaccine in infants and toddlers, irrespective of vaccination schedule. It provides durable protection against hepatitis B. Hexyon® can be used for a mixed primary series of hexavalent-pentavalent-hexavalent vaccines or as a booster in infants primed with Infanrix hexa™ or pentavalent (whole-cell or acellular pertussis) vaccines. Coadministration of Hexyon® with other common childhood vaccines did not affect immune response to any vaccines. Hexyon® has a good reactogenicity/safety profile. The immunogenicity and safety profile of Hexyon® was similar to that of several approved vaccines, including Infanrix hexa™. However, Hexyon® offers the convenience of full-liquid, ready-to-use formulation, which may minimize vaccination errors and preparation time. Thus, Hexyon® is a convenient, useful option for vaccination against childhood diseases caused by six major pathogens.
During the review process, the manufacturer of Hexyon® was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
Yahiya Syed is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 3.European Medicines Agency. Hexyon suspension for injection: summary of product characteristics. 2013. https://www.ema.europa.eu. Accessed 10 Jun 2019.
- 15.Paterson L. The European medicines agency’s article 58 procedure: reflections on the first approval for a vaccine. Regul Rapporteur. 2013;10(4):19–23.Google Scholar
- 16.Sanofi Pasteur. Fact sheet: a fully-liquid, ready to use 6-in-1 pediatric vaccine. 2018. https://www.sanofipasteur.com. Accessed 10 Jun 2019.
- 18.Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. Pediatr Infect Dis J. 2011;30(6):e88–96.CrossRefPubMedGoogle Scholar
- 20.Kosalaraksa P, Thisyakorn U, Benjaponpitak S, et al. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants. Int J Infect Dis. 2011;15(4):e249–56.CrossRefPubMedGoogle Scholar
- 23.Madhi SA, Koen A, Cutland C, et al. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15–18 months of age in healthy South African infants. Pediatr Infect Dis J. 2013;32(8):889–97.PubMedGoogle Scholar
- 24.Kosalaraksa P, Chokephaibulkit K, Benjaponpitak S, et al. Persistence of hepatitis B immune memory until 9–10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP ~ T vaccination at 2, 4 and 6 months. Hum Vaccin Immunother. 2018;14(5):1257–65.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.European Medicines Agency. Hexyon: assessment report (EMA/373968/2013). 2013. https://www.ema.europa.eu. Accessed 10 Jun 2019.
- 27.Martinelli D, Fortunato F, Moffa L, et al. Post-marketing surveillance of Hexyon vaccine administered in preterm infants in the apulia region (Italy) in 2017 [abstract no. ESPID19-0212 + poster]. In: 37th Annual Meeting of the European Society for Paediatric Infectious Diseases. 2019.Google Scholar
- 29.European Centre for Disease Prevention and Control. Vaccination schedules for individual European countries and specific age groups. 2019. https://ecdc.europa.eu. Accessed 20 May 2019.
- 35.Lyabis O, Feroldi E, Jordanov E, et al. Long-term hepatitis B immunity after different immunization schedules with Sanofi Pasteur’s hexavalent DTAP-IPV-HB-PRP-T vaccine: a review [abstract no. 19-0890]. In: 37th Annual Meeting of the European Society for Paediatric Infectious Disease (ESPID). 2019.Google Scholar
- 37.World Health Organization. Pertussis vaccines: WHO position paper—August 2015. Wkly Epidemiol Rec. 2015;90(35):433–60.Google Scholar
- 38.Smittskyddsinstitutet. Pertussis surveillance in Sweden: progress report October 1997—September 2006 with an executive summary. 2008. https://www.folkhalsomyndigheten.se. Accessed 10 Jun 2019.
- 43.World Health Organization. Haemophilus influenzae type b (Hib) vaccination position paper—September 2013. Wkly Epidemiol Rec. 2013;88(39):413–28.Google Scholar
- 47.Lyabis O, Bonanni P, Icardi P, et al. Role of fully liquid ready-to-use vaccine and vaccines that require reconstitution in minimization of vaccination errors: focused literature review [abstract no. 19-0526]. In: 37th Annual Meeting of the European Society for Paediatric Infectious Disease (ESPID). 2019.Google Scholar
- 49.Lloyd AJ, Nafees B, Ziani E, et al. What are the preferences of health care professionals in Germany regarding fully liquid, ready-to-use hexavalent pediatric vaccine versus hexavalent pediatric vaccine that needs reconstitution? Patient Prefer Adherence. 2015;9:1517–24.PubMedPubMedCentralGoogle Scholar